Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ursapharm arzneimittel gmbh - tetryzolinhydrochlorid - augentropfen - tetryzolinhydrochlorid 0.5mg

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ursapharm arzneimittel gmbh - tetryzolinhydrochlorid - augentropfen - tetryzolinhydrochlorid 0.5mg

Kypros - gresk - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

m k stavrinos ltd (0000003059) 3 eracleous, lefkosia, 1501, 21074 - tetryzoline hydrochloride - eye drops - 0.5mg/ml - tetryzoline hydrochloride (0000522485) 0.5mg - tetryzoline

Taiwan - kinesisk - 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

明盟實業有限公司 台北市信義路四段３８０號７樓 (14085628) - tetryzoline hydrochloride (eq to tetrahydrozoline hydrochloride) - 點眼液劑 - tetryzoline hydrochloride (eq to tetrahydrozoline hydrochloride) (5232000330) 0.5mg - tetryzoline, combinations - 眼睛受刺激、結膜炎、結膜充血

USA - engelsk - NLM (National Library of Medicine)

medical purchasin solutions, llc - vasopressin, unspecified (unii: y87y826h08) (vasopressin, unspecified - unii:y87y826h08) - vasostrict ® is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines. vasostrict ® is contraindicated in patients with known allergy or hypersensitivity to 8-l-arginine vasopressin or chlorobutanol. pregnancy category c risk summary: there are no adequate or well-controlled studies of vasostrict ® in pregnant women. it is not known whether vasopressin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. animal reproduction studies have not been conducted with vasopressin [see clinical pharmacology (12.3)]. clinical considerations: because of increased clearance of vasopressin in the second and third trimester, the dose of vasostrict ® may need to be up-titrated to doses exceeding 0.1 units/minute in post-cardiotomy shock and 0.07 units/minute in septic

USA - engelsk - NLM (National Library of Medicine)

par pharmaceutical, inc. - vasopressin, unspecified (unii: y87y826h08) (vasopressin, unspecified - unii:y87y826h08) - vasostrict® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. vasostrict® 10 ml multiple dose vial is contraindicated in patients with known allergy or hypersensitivity to 8‑l-arginine vasopressin or chlorobutanol. the 1 ml single dose vial, 50 ml and 100 ml pre-mixed single dose vial does not contain chlorobutanol and is therefore contraindicated only in patients with a known allergy or hypersensitivity to 8-l-arginine vasopressin. risk summary there are no available data on vasostrict® use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.  animal reproduction studies have not been conducted with vasopressin. clinical considerations dose adjustments during pregnancy and the postpartum period: because of increased clearance of vasopressin in the second and third trimester, the dose of vasostrict® may need to be increased [see dosage and administration (2.2) and clinical pharmacology (12.3)] . maternal adverse reactions: vasostrict® may produce tonic uterine contractions that could threaten the continuation of pregnancy. there are no data on the presence of vasopressin injection in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. safety and effectiveness of vasostrict® in pediatric patients with vasodilatory shock have not been established. clinical studies of vasopressin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see warnings and precautions (5), adverse reactions (6), and clinical pharmacology (12.3)] .

USA - engelsk - NLM (National Library of Medicine)

medical purchasing solutions, llc - vasopressin, unspecified (unii: y87y826h08) (vasopressin, unspecified - unii:y87y826h08) - vasostrict ® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. vasostrict ® 10 ml multiple dose vial is contraindicated in patients with known allergy or hypersensitivity to 8‑l-arginine vasopressin or chlorobutanol.  the 1 ml single dose vial does not contain chlorobutanol and is therefore contraindicated only in patients with a known allergy or hypersensitivity to 8-l-arginine vasopressin. risk summary there are no available data on vasostrict ® use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted. clinical considerations dose adjustments during pregnancy and the postpartum period: because of increased clearance of vasopressin in the second and third trimester, the dose of vasostrict® may need to be increased [see dosage and

USA - engelsk - NLM (National Library of Medicine)

par pharmaceutical, inc. - vasopressin, unspecified (unii: y87y826h08) (vasopressin, unspecified - unii:y87y826h08) - vasostrict® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. vasostrict® 10 ml multiple dose vial is contraindicated in patients with known allergy or hypersensitivity to 8‑l-arginine vasopressin or chlorobutanol.  the 1 ml single dose vial does not contain chlorobutanol and is therefore contraindicated only in patients with a known allergy or hypersensitivity to 8-l-arginine vasopressin. risk summary there are no available data on vasostrict® use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.  animal reproduction studies have not been conducted with vasopressin. clinical considerations dose adjustments during pregnancy and the postpartum period: because of increased clearance of vasopressin in the second and third trimester, the dose of vasostrict® may need to be increased [see dosage and administration (2.2) and clinical pharmacology (12.3)] .

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios intervet, s.a. - ramipril - comprimido - excipientes: hidroxipropil metilcelulosa (hipromelosa), almidon pregelatinizado, celulosa microcristalina, aroma sabor carne, oxido de hierro rojo (e 172, ci=77491), silice coloidal anhidra, fumarato de estearilo y sodio - ramipril - perros

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

intervet nederland b.v. - ramipril - tablet - ramipril 0,625 mg/stuk, - ramipril - honden